49 results on '"M. Mulcahy"'
Search Results
2. Familial Chordoma
3. Supplementary Figure Legends from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
4. Supplementary Figure 4 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
5. Data from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
6. Supplementary Figure 2 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
7. Supplementary Figure 5 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
8. Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
9. Supplementary Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
10. Supplementary Figure Legends from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
11. Supplementary Figure 4 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
12. Supplementary Figure 2 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
13. Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
14. Supplementary Figure 3 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
15. Supplementary Figure 1 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
16. Data from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
17. Supplementary figure 1 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
18. Supplementary Figure 2 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
19. Supplementary Figure 1 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
20. Supplementary Figure 3 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
21. Supplementary Figure 2 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
22. Supplementary Figure 6 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
23. Supplementary figure 1 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
24. Supplementary Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
25. Supplementary Figure 6 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
26. Supplementary Figure 5 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
27. Radiation Therapy for Young Children Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant for Primary Brain Tumors
28. ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY
29. ATRT-20. CDK7 INHIBITION IN AT/RT
30. Lactational metformin exposure programs offspring white adipose tissue glucose homeostasis and resilience to metabolic stress in a sex-dependent manner
31. Medical and rehabilitation interventions in pediatric central nervous system radiation necrosis: A case report
32. Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway
33. MEK inhibition with trametinib is a successful therapy in ganglioglioma
34. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway
35. Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
36. LGG-37. ASSESSMENT OF EARLY STAGE AUTOPHAGY INHIBITION IN BRAFV600E BRAIN TUMOR CELL RESPONSE TO CHEMOTHERAPY
37. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis
38. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy
39. Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors
40. Targeting autophagy in cancer
41. Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma
42. Abstract A25: Autophagy inhibition reverses resistance to targeted BRAF therapy in CNS tumors
43. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics
44. Using BRAFV600Eas a marker of autophagy dependence in pediatric brain tumors
45. Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
46. Pediatric Brainstem Gangliogliomas ShowBRAFV600EMutation in a High Percentage of Cases
47. Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age
48. Modulation of pediatric brain tumor autophagy and chemosensitivity
49. Targeting autophagy during cancer therapy to improve clinical outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.